Latest news

• Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

  This increase can be attributed to Lily’s key growth products, including Trulicity, Verzenio, Olumiant, Tyvyt, Emgality, Jardiance, Retevmo, Cyramza and Taltz.

• Modest meeting sees only two drugs recommended by CHMP

  one generic medicine at its latest meeting, with a surprise negative opinion for Eli Lilly’s migraine med Emgality. ... As the CHMP aptly put it, "the benefits of Emgality (…) did not outweigh its risks”.

• Biohaven gets FDA approval for migraine drug Nurtec ODT

  s Emgality (galcanezumab) – as well as Lundbeck’s just-approved intravenous therapy Vyepti (eptinezumab).

• Lundbeck gets US approval for migraine drug at heart of Alder takeover

  It’s also the first and only intravenously-administered CGRP antibody, as the current three drugs – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab) – are ... Teva meanwhile said Ajovy

• Lilly launches migraine med Reyvow at $640 per eight-pill pack

  It also predicts Emgality could hit $1.2bn by 2024, with Ajovy forecast to reach $962m. ... Emgality could make further gains after it won the race to claim the first approval of a drug in the class for cluster headache.